• Initial data shows Archer's blood potassium graphene Biochip can be successfully built on silicon
• Silicon-based devices achieved potassium sensing accuracy of ±0.3 mM, matching graphene gFET results and CLIA clinical standard
• Silicon devices had faster readout times than current graphene gFET Biochip

Archer Materials Limited (ASX: AXE), a quantum technology company, has delivered successful results from the first stage of the silicon Biochip project. The company has partnered with IMEC, which showed that the silicon devices meet blood potassium accuracy requirements. Archer and IMEC achieved a potassium sensing accuracy of ±0.3 mM, matching both its latest graphene field effect transistor (gFET) performance and the clinical CLIA standard. This is the first major step in accelerating development and commercialisation for the lead application of Archer's Biochip platform. These silicon devices achieve this accuracy with faster readout times than the current scheme used on the gFET Biochip, demonstrating strong potential for a high-performance, scalable, and clinically compliant biosensor platform. IMEC has fabricated three distinct types of Biochip-based sensor devices using its well-established wafer-scale silicon wafer processing technology. These chips are subsequently modified, functionalised, and tested using Archer's proprietary methods to assess their potassium-sensing performance. In addition to equivalent accuracy to gFET Biochip devices and the CLIA testing requirements, the silicon devices had shorter conditioning and stabilisation times, performing in around 30 minutes, which is a significant improvement in current lab testing of the gFET devices. These outcomes represent important progress on two major fronts. First, these results show that Archer's blood potassium Biochip sensor can be built around a silicon platform, thus de-risking Archer's Biochip supply chain, reducing final sensor cost, and allowing acceleration of the Biochip development towards market. Second, the engineering and IP development around the functionalisation (added layers and processes to make the Biochip gFET into a sensor) of graphene-based devices has been successfully leveraged and can be transferred to a silicon platform.

Archer will now begin planning the regulatory approvals pathway and undertake a major productisation project with IMEC for 2026, focused on potassium sensing for chronic kidney disease. This initiative aims to deliver a silicon-based potassium Biochip and sensor designed for both point-of-care and at-home diagnostic. In the remaining months of the current feasibility project, Archer and IMEC will focus on refining device processing and measurement techniques to further validate the silicon Biochip performance. The teams will also complete and test two additional silicon Biochip types, enhancing measurement precision and speed. These results will provide critical input to define the productisation pathway toward a fully integrated sensor system.